Loading…
Targeted Therapies in Low-Grade Serous Ovarian Cancers
Opinion Statement Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has...
Saved in:
| Published in: | Current treatment options in oncology 2024-07, Vol.25 (7), p.854-868 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c356t-f67a580802fc5ab50581699f6778d129ea284cb53a2b83c2a19318e1fabe26ae3 |
| container_end_page | 868 |
| container_issue | 7 |
| container_start_page | 854 |
| container_title | Current treatment options in oncology |
| container_volume | 25 |
| creator | Gonzalez, Anna Nagel, Christa I. Haight, Paulina J. |
| description | Opinion Statement
Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease. |
| doi_str_mv | 10.1007/s11864-024-01205-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11236859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3067913382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-f67a580802fc5ab50581699f6778d129ea284cb53a2b83c2a19318e1fabe26ae3</originalsourceid><addsrcrecordid>eNp9kUtPAjEUhRujEUT_gAsziRs3o31MXytjiKIJCQtx3dwZ7sAQmMEWMP57iyA-FqZpetP73dOeHELOGb1mlOqbwJhRWUp53IxTmWYHpM2kyFLFtT7c1FynXHPbIichTCnlMqP2mLSEMcrG1SZqCH6MSxwlwwl6WFQYkqpO-s1b2vMwwuQZfbMKyWANvoI66UJdoA-n5KiEWcCz3dkhLw_3w-5j2h_0nrp3_bQQUi3TUmmQhhrKy0JCLqk0TFkbr7UZMW4RuMmKXArguREFB2YFM8hKyJErQNEht1vdxSqf46jAeulh5ha-moN_dw1U7nenriZu3KwdY1woI21UuNop-OZ1hWHp5lUocDaDGqMxJ6jSlglheEQv_6DTZuXr6C9S2ighdQQ7hG-pwjcheCz3v2HUbXJx21xczMV95uKyOHTx08d-5CuICIgtEGKrHqP_fvsf2Q_isZdL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3078635713</pqid></control><display><type>article</type><title>Targeted Therapies in Low-Grade Serous Ovarian Cancers</title><source>Springer Nature</source><creator>Gonzalez, Anna ; Nagel, Christa I. ; Haight, Paulina J.</creator><creatorcontrib>Gonzalez, Anna ; Nagel, Christa I. ; Haight, Paulina J.</creatorcontrib><description>Opinion Statement
Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.</description><identifier>ISSN: 1527-2729</identifier><identifier>ISSN: 1534-6277</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-024-01205-4</identifier><identifier>PMID: 38869696</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers, Tumor ; Chemotherapy ; Clinical trials ; Clinical Trials as Topic ; Combined Modality Therapy - adverse effects ; Cystadenocarcinoma, Serous - drug therapy ; Cystadenocarcinoma, Serous - pathology ; Cystadenocarcinoma, Serous - therapy ; Disease Management ; Female ; Humans ; Medicine ; Medicine & Public Health ; Molecular Targeted Therapy - methods ; Neoplasm Grading ; Neoplasm Staging ; Oncology ; Ovarian cancer ; Ovarian carcinoma ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Topical Collection on Gynecologic Cancers ; Treatment Outcome</subject><ispartof>Current treatment options in oncology, 2024-07, Vol.25 (7), p.854-868</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c356t-f67a580802fc5ab50581699f6778d129ea284cb53a2b83c2a19318e1fabe26ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38869696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonzalez, Anna</creatorcontrib><creatorcontrib>Nagel, Christa I.</creatorcontrib><creatorcontrib>Haight, Paulina J.</creatorcontrib><title>Targeted Therapies in Low-Grade Serous Ovarian Cancers</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion Statement
Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.</description><subject>Biomarkers, Tumor</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Combined Modality Therapy - adverse effects</subject><subject>Cystadenocarcinoma, Serous - drug therapy</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Cystadenocarcinoma, Serous - therapy</subject><subject>Disease Management</subject><subject>Female</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian carcinoma</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Topical Collection on Gynecologic Cancers</subject><subject>Treatment Outcome</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kUtPAjEUhRujEUT_gAsziRs3o31MXytjiKIJCQtx3dwZ7sAQmMEWMP57iyA-FqZpetP73dOeHELOGb1mlOqbwJhRWUp53IxTmWYHpM2kyFLFtT7c1FynXHPbIichTCnlMqP2mLSEMcrG1SZqCH6MSxwlwwl6WFQYkqpO-s1b2vMwwuQZfbMKyWANvoI66UJdoA-n5KiEWcCz3dkhLw_3w-5j2h_0nrp3_bQQUi3TUmmQhhrKy0JCLqk0TFkbr7UZMW4RuMmKXArguREFB2YFM8hKyJErQNEht1vdxSqf46jAeulh5ha-moN_dw1U7nenriZu3KwdY1woI21UuNop-OZ1hWHp5lUocDaDGqMxJ6jSlglheEQv_6DTZuXr6C9S2ighdQQ7hG-pwjcheCz3v2HUbXJx21xczMV95uKyOHTx08d-5CuICIgtEGKrHqP_fvsf2Q_isZdL</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Gonzalez, Anna</creator><creator>Nagel, Christa I.</creator><creator>Haight, Paulina J.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240701</creationdate><title>Targeted Therapies in Low-Grade Serous Ovarian Cancers</title><author>Gonzalez, Anna ; Nagel, Christa I. ; Haight, Paulina J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-f67a580802fc5ab50581699f6778d129ea284cb53a2b83c2a19318e1fabe26ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomarkers, Tumor</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Combined Modality Therapy - adverse effects</topic><topic>Cystadenocarcinoma, Serous - drug therapy</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Cystadenocarcinoma, Serous - therapy</topic><topic>Disease Management</topic><topic>Female</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian carcinoma</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Topical Collection on Gynecologic Cancers</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez, Anna</creatorcontrib><creatorcontrib>Nagel, Christa I.</creatorcontrib><creatorcontrib>Haight, Paulina J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez, Anna</au><au>Nagel, Christa I.</au><au>Haight, Paulina J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Therapies in Low-Grade Serous Ovarian Cancers</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>25</volume><issue>7</issue><spage>854</spage><epage>868</epage><pages>854-868</pages><issn>1527-2729</issn><issn>1534-6277</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion Statement
Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38869696</pmid><doi>10.1007/s11864-024-01205-4</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-2729 |
| ispartof | Current treatment options in oncology, 2024-07, Vol.25 (7), p.854-868 |
| issn | 1527-2729 1534-6277 1534-6277 1534-5277 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11236859 |
| source | Springer Nature |
| subjects | Biomarkers, Tumor Chemotherapy Clinical trials Clinical Trials as Topic Combined Modality Therapy - adverse effects Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - pathology Cystadenocarcinoma, Serous - therapy Disease Management Female Humans Medicine Medicine & Public Health Molecular Targeted Therapy - methods Neoplasm Grading Neoplasm Staging Oncology Ovarian cancer Ovarian carcinoma Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Topical Collection on Gynecologic Cancers Treatment Outcome |
| title | Targeted Therapies in Low-Grade Serous Ovarian Cancers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T23%3A32%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Therapies%20in%20Low-Grade%20Serous%20Ovarian%20Cancers&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Gonzalez,%20Anna&rft.date=2024-07-01&rft.volume=25&rft.issue=7&rft.spage=854&rft.epage=868&rft.pages=854-868&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-024-01205-4&rft_dat=%3Cproquest_pubme%3E3067913382%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-f67a580802fc5ab50581699f6778d129ea284cb53a2b83c2a19318e1fabe26ae3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3078635713&rft_id=info:pmid/38869696&rfr_iscdi=true |